Latest Period
Q1 2026
Security Snapshot
Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) Institutional Ownership
CUSIP: 23954D109
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
204
Shares (Excl. Options)
85,594,196
Price
$21.44
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- DAWN
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 85,594,196
- Total 13F value
- $1,835,029,089
- Portfolio coverage rank
- 0.01%
- Share change
- -1,041,785
- Value change
- +$258,673,107
- Number of holders
- 204
- Shares outstanding
- 103,269,345
- SEC-reported price per share
- $21.53
- Insider filing price
- $21.53
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DAWN - Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 23954D109.
- 204 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 184 to 204 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $758,407,820 to $1,835,029,089.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 204 institutions filings for Q1 2026.
Security key
23954D109
Latest holder period
Q1 2026
13F holders
204
13D/G owners
4
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23954D109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
DAWN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | +22% | $38,061,315 | +$6,751,002 | 5,849,917 | +22% | BlackRock, Inc. | 30 Jun 2025 |
| GLAZER CAPITAL, LLC | 5.4% | $64,576,985 | 5,615,390 | Glazer Capital, LLC | 12 Mar 2026 | |||
| Vestal Point Capital, LP | 5.1% | $55,068,000 | 5,200,000 | Vestal Point Capital, LP | 31 Dec 2025 | |||
| FMR LLC | 0% | -93% | $506,835 | -$122,065,810 | 23,640 | -100% | FMR LLC | 31 Mar 2026 |
As of 31 Mar 2026, 204 institutional investors reported holding 85,594,196 shares of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN). This represents 83% of the company’s total 103,269,345 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6.8% | 7,044,487 | -20% | 0% | $151,033,802 |
| GLAZER CAPITAL, LLC | 4.5% | 4,683,687 | 2.2% | $100,418,000 | |
| FIL Ltd | 4% | 4,131,907 | 0.07% | $88,588,086 | |
| Kryger Capital LLC | 3.8% | 3,896,485 | 0% | 5.9% | $83,540,638 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.6% | 3,723,131 | 0% | 0.94% | $79,823,929 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 3,357,684 | 0% | 0% | $71,988,745 |
| JPMORGAN CHASE & CO | 3% | 3,134,753 | +7101% | 0% | $67,146,410 |
| STATE STREET CORP | 2.8% | 2,869,876 | -33% | 0% | $61,530,141 |
| Balyasny Asset Management L.P. | 2.5% | 2,625,235 | +76% | 0.11% | $56,285,038 |
| AQR Arbitrage LLC | 2.4% | 2,462,154 | 0.87% | $52,788,582 | |
| UBS Group AG | 2.2% | 2,305,123 | +1250% | 0.01% | $49,421,837 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2% | 2,095,813 | 0% | 0% | $44,934,231 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,954,735 | +4.1% | 0% | $41,918,714 |
| Qube Research & Technologies Ltd | 1.9% | 1,954,552 | +31% | 0.06% | $41,905,595 |
| MILLENNIUM MANAGEMENT LLC | 1.9% | 1,927,557 | +43% | 0.03% | $41,326,822 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 1,902,868 | +76% | 0% | $40,797,491 |
| O'Connor Alternative Investments LLC | 1.8% | 1,867,553 | 0% | 3.5% | $40,040,336 |
| Nuveen, LLC | 1.8% | 1,823,998 | +249% | 0.01% | $39,106,518 |
| PERCEPTIVE ADVISORS LLC | 1.7% | 1,755,799 | 0.74% | $37,644,331 | |
| ODDO BHF ASSET MANAGEMENT SAS | 1.5% | 1,550,000 | 1.3% | $33,232,000 | |
| SOROS FUND MANAGEMENT LLC | 1.5% | 1,539,100 | 0.45% | $32,998,304 | |
| First Trust Capital Management L.P. | 1.4% | 1,496,007 | 1.7% | $32,074,390 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 1,296,984 | -0.62% | 0.04% | $27,807,337 |
| GOLDMAN SACHS GROUP INC | 0.95% | 979,238 | -35% | 0% | $20,994,863 |
| DAFNA Capital Management LLC | 0.95% | 978,463 | -2.1% | 4.8% | $20,978,247 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q1 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 85,594,196 | $1,835,029,089 | +$258,673,107 | $21.44 | 204 |
| 2025 Q4 | 81,407,499 | $758,407,820 | -$20,471,774 | $9.32 | 184 |
| 2025 Q3 | 85,449,652 | $602,397,711 | -$3,520,489 | $7.05 | 169 |
| 2025 Q2 | 86,186,499 | $560,206,343 | -$67,566,968 | $6.50 | 173 |
| 2025 Q1 | 94,058,917 | $745,890,533 | -$40,487,714 | $7.93 | 183 |
| 2024 Q4 | 93,739,417 | $1,187,690,667 | -$5,879,821 | $12.67 | 163 |
| 2024 Q3 | 92,050,053 | $1,283,687,781 | +$239,491,695 | $13.93 | 165 |
| 2024 Q2 | 74,705,046 | $1,029,464,955 | +$17,373,333 | $13.78 | 155 |
| 2024 Q1 | 72,782,347 | $1,202,300,406 | -$58,498,635 | $16.52 | 147 |
| 2023 Q4 | 76,570,666 | $1,117,957,204 | -$50,224,829 | $14.60 | 138 |
| 2023 Q3 | 77,547,732 | $951,517,363 | -$22,223,998 | $12.27 | 127 |
| 2023 Q2 | 78,803,713 | $941,011,552 | +$208,122,003 | $11.94 | 136 |
| 2023 Q1 | 61,209,087 | $818,137,120 | -$10,189,943 | $13.37 | 122 |
| 2022 Q4 | 59,797,551 | $1,286,831,022 | -$37,719,296 | $21.52 | 105 |
| 2022 Q3 | 60,343,678 | $1,208,648,617 | +$24,007,409 | $20.03 | 87 |
| 2022 Q2 | 59,307,013 | $1,061,573,186 | +$302,547,160 | $17.90 | 80 |
| 2022 Q1 | 43,302,427 | $429,553,897 | +$13,144,675 | $9.92 | 66 |
| 2021 Q4 | 41,477,196 | $698,277,000 | +$74,959,681 | $16.85 | 57 |
| 2021 Q3 | 19,043,827 | $450,147,328 | +$32,649,130 | $23.73 | 43 |
| 2021 Q2 | 17,724,839 | $401,085,000 | +$401,084,962 | $22.77 | 32 |